Musculoskeletal

Sjogren syndrome: diagnosis and management

Clinical Overview and When to Suspect Sjögren Syndrome

— Prevalence ~0.5–1% of US adults; female:male ratio ~9:1

— Peak onset 40–60 years; second smaller peak in adolescence

— Second most common systemic autoimmune disease after RA

— Primary SS: isolated disease

— Secondary SS: occurs alongside another connective tissue disease — most commonly RA, SLE, systemic sclerosis

— Middle-aged woman with >3 months of dry eyes/mouth, dental caries at unusual sites (cervical/incisal), parotid swelling, or recurrent oral candidiasis

— Unexplained bilateral parotid enlargement (especially recurrent and non-tender)

— Positive ANA + anti-Ro/SSA found on workup of another suspected autoimmune disease

— Hypergammaglobulinemia, elevated ESR with normal CRP, or polyclonal gammopathy on SPEP

— Cytopenias, RTA, interstitial nephritis, peripheral neuropathy, or interstitial lung disease in a woman with sicca symptoms

— Neonate with congenital heart block → mother has anti-Ro/SSA, often subclinical SS

— CD4+ T cell-driven glandular destruction with ectopic germinal centers

— B-cell hyperactivity → autoantibodies, hypergammaglobulinemia, and 44-fold increased risk of MALT lymphoma

Definition: Chronic autoimmune exocrinopathy with lymphocytic infiltration of exocrine glands (lacrimal, salivary), producing the sicca complex (xerophthalmia, xerostomia), plus a wide range of extraglandular manifestations.

Epidemiology:

Primary vs secondary:

When to suspect on Step 3:

Pathophysiology pearls:

Step 3 management: Once sicca symptoms persist >3 months in an adult, screen with anti-Ro/SSA, anti-La/SSB, ANA, RF, and refer to ophthalmology for objective ocular dryness testing rather than treating empirically with artificial tears alone.

Board pearl: Sjögren is the great mimicker—it can present first with renal tubular acidosis, sensory ataxic neuropathy, or interstitial lung disease before sicca symptoms become prominent.

Presentation Patterns and Key History

— Xerophthalmia: gritty/sandy sensation, photophobia, blurred vision improving with blinking, difficulty wearing contacts, morning eyelid crusting

— Xerostomia: difficulty swallowing dry foods without water ("cracker sign"), need to sip water at night, altered taste (dysgeusia), accelerated dental decay, recurrent oral candidiasis with angular cheilitis

— Recurrent or persistent bilateral parotid swelling; unilateral firm/fixed enlargement raises concern for lymphoma

— Submandibular gland involvement less common but possible

— MSK: arthralgias, non-erosive symmetric polyarthritis (mimics early RA)

— Skin: annular erythema, palpable purpura (cryoglobulinemic vasculitis), Raynaud (~30%)

— Pulmonary: chronic dry cough, NSIP/UIP-pattern ILD, lymphocytic interstitial pneumonia

— Renal: distal (type 1) RTA with hypokalemia, nephrogenic DI, tubulointerstitial nephritis; GN less common (membranoproliferative with cryoglobulinemia)

— Neuro: small fiber and sensory ataxic neuropathy, trigeminal neuropathy, rarely transverse myelitis or aseptic meningitis

— Heme: cytopenias, polyclonal hypergammaglobulinemia, cryoglobulinemia

— OB: recurrent pregnancy loss, anti-Ro–mediated neonatal lupus/CHB

— Anticholinergics, antihistamines, TCAs, opioids, diuretics → drug-induced sicca

— Prior head/neck radiation, hepatitis C, HIV, IgG4-related disease, sarcoidosis

Sicca symptoms (cardinal):

Glandular enlargement:

Extraglandular manifestations (40–60% of patients):

Constitutional: profound fatigue (often the most disabling symptom), low-grade fevers, weight loss

Drug/exposure history to elicit:

Key distinction: Drug-induced sicca is dose-related, lacks autoantibodies, and resolves with discontinuation; Sjögren is chronic with serologic evidence and objective glandular dysfunction.

Board pearl: Ask specifically about need to sip water to swallow dry food and dental visits in past 2 years—high-yield positives that anchor a clinical diagnosis on the exam.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Dry, sticky, erythematous mucosa; tongue depressor adheres to buccal mucosa

— Fissured, depapillated ("cobblestone") tongue; angular cheilitis

— Dental caries at cervical margins and incisal edges (atypical sites)

— Absent salivary pooling in the floor of mouth; milky/scant expression from Stensen/Wharton ducts

— Oral candidiasis (erythematous more than pseudomembranous in chronic xerostomia)

— Conjunctival injection, blepharitis, decreased tear meniscus

— Schirmer test at bedside: <5 mm wetting in 5 min on filter paper is abnormal

— Slit-lamp: punctate keratopathy on lissamine green/rose bengal staining

— Bilateral, firm, non-tender parotid enlargement; pinna lifted outward

— Red flag: persistent unilateral, hard, fixed, or rapidly enlarging gland → lymphoma workup

Oral exam:

Ocular exam:

Glandular exam:

Skin: palpable purpura on lower extremities (cryoglobulinemic vasculitis), annular erythema, livedo

MSK: symmetric tender MCP/PIP joints without erosions or deformity

Neuro: stocking-glove sensory loss, sensory ataxia with positive Romberg (dorsal root ganglionopathy), reduced pinprick (small fiber)

Pulmonary: fine bibasilar crackles if ILD; consider PFTs

Cardiovascular/hemodynamics: generally normal; orthostatic hypotension can occur with autonomic neuropathy—check orthostatics in patients with fatigue/dizziness

Lymph nodes: persistent or growing lymphadenopathy >1.5 cm is a lymphoma red flag

Step 3 management: During an office visit for suspected SS, document Schirmer, oral exam findings, parotid size, lymph node survey, and skin/joint exam—these anchor the diagnosis and identify high-risk features that require expedited referral.

Board pearl: Tongue depressor sticks to buccal mucosa + cervical caries in a 50-year-old woman is a near-pathognomonic exam vignette for Sjögren.

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Anti-Ro/SSA (70%) and anti-La/SSB (40%) — Ro is more sensitive and the primary criterion antibody

— ANA positive in ~70%; RF positive in ~50% (can confound RA workup)

— Anti-CCP negative (helps distinguish from RA)

— Elevated ESR with often-normal CRP (clue!)

— Polyclonal hypergammaglobulinemia on SPEP; quantitative IgG often elevated

— Low C3/C4 → poor prognostic marker and lymphoma risk

— Cryoglobulins if purpura, neuropathy, or GN

— Cytopenias (mild leukopenia common), anemia of chronic disease

— Hypokalemia + non-anion-gap metabolic acidosis → screen for distal RTA with urine pH (>5.5 despite acidemia)

— Elevated Cr or proteinuria → renal involvement

— Schirmer ≤5 mm/5 min

— Ocular staining score ≥5 (lissamine green/fluorescein)

— Unstimulated whole salivary flow ≤0.1 mL/min over 15 min

— Salivary gland ultrasound: hypoechoic foci, heterogeneous parenchyma (increasingly used, noninvasive)

— CXR if cough/dyspnea; HRCT chest for suspected ILD

— MRI/CT salivary glands if asymmetric enlargement or lymphoma concern

Serologies (first-line):

Inflammation/immune markers:

CBC/CMP:

UA: glycosuria without hyperglycemia (proximal tubular dysfunction), low specific gravity (nephrogenic DI)

Objective ocular testing (ophthalmology referral):

Objective oral testing:

Imaging adjuncts:

ECG: check in patients with anti-Ro/SSA who are pregnant (fetal monitoring) or with palpitations (rare conduction abnormalities)

Hepatitis C and HIV: must rule out as sicca mimics before labeling primary SS

Step 3 management: A reasonable initial panel in suspected SS is CBC, CMP, UA, ESR/CRP, SPEP, ANA, anti-Ro/La, RF, anti-CCP, C3/C4, HCV Ab, HIV—plus Schirmer and salivary flow.

Board pearl: Anti-Ro positivity in a pregnant patient mandates fetal echo surveillance from 16–26 weeks for congenital heart block.

Diagnostic Workup — Advanced or Confirmatory Studies

— Labial salivary gland biopsy with focus score ≥1 (focus = ≥50 lymphocytes/4 mm²) — 3 points

— Anti-Ro/SSA positive — 3 points

— Ocular staining score ≥5 in at least one eye — 1 point

— Schirmer ≤5 mm/5 min in at least one eye — 1 point

— Unstimulated whole salivary flow ≤0.1 mL/min — 1 point

— Exclusions: prior head/neck radiation, active HCV, HIV, sarcoidosis, amyloidosis, GVHD, IgG4-related disease

— Gold-standard confirmatory test, especially in seronegative patients

— Performed via lower lip mucosa; complications include transient lip numbness

— Focus score quantifies periductal lymphocytic aggregates

— Increasingly accepted; OMERACT scoring of parenchymal inhomogeneity

— Useful to monitor for nodular changes suggestive of lymphoma

— HRCT chest + PFTs with DLCO for suspected ILD

— Nerve conduction + skin biopsy with intraepidermal nerve fiber density for small fiber neuropathy

— Renal biopsy if unexplained AKI, proteinuria, or RTA with progressive dysfunction → tubulointerstitial nephritis

— Persistent parotid enlargement, lymphadenopathy >1.5 cm, splenomegaly

— Cryoglobulinemia, low C4, monoclonal gammopathy, palpable purpura, lymphopenia

— Excisional or core biopsy preferred over FNA for lymphoma diagnosis

2016 ACR/EULAR classification criteria (score ≥4 classifies as SS; requires sicca symptoms or suspicious extraglandular finding as entry):

Minor salivary gland (labial) biopsy:

Salivary gland ultrasound:

Sialography/scintigraphy: largely supplanted but may appear on exams as historical tests

Advanced workups based on organ involvement:

Lymphoma surveillance triggers (biopsy lymph node or persistent parotid mass):

Key distinction: Seronegative Sjögren is real—about 30% lack anti-Ro/La and require labial biopsy for classification.

Board pearl: A focus score ≥1 on labial gland biopsy is worth 3 points and can clinch the diagnosis when serologies are negative.

Risk Stratification or First-Line Management Logic

— Mild/glandular-only disease: sicca symptoms, fatigue, arthralgias → symptomatic therapy

— Systemic/extraglandular disease: ILD, GN, vasculitis, severe neuropathy, cytopenias, RTA → immunosuppression

— Used to score systemic activity across 12 domains

— Guides escalation; ESSDAI ≥5 generally indicates moderate-to-high activity warranting systemic therapy

— Strongest predictors: persistent parotid enlargement, palpable purpura, low C4, cryoglobulinemia, lymphopenia, monoclonal gammopathy, germinal centers on biopsy, CD4:CD8 ratio <0.8

— Lifetime non-Hodgkin lymphoma risk ~5–10% (mostly MALT in parotid)

— Step 1: Patient education + symptomatic sicca therapy + dental/ophtho preventive care

— Step 2: Hydroxychloroquine for fatigue, arthralgias, rash

— Step 3: Glucocorticoids + steroid-sparing agents (MTX, azathioprine, MMF) for organ involvement

— Step 4: Rituximab or cyclophosphamide for refractory or severe systemic disease (vasculitis, severe neuropathy, ILD progression)

— Eliminate or substitute anticholinergic medications (antihistamines, TCAs, antimuscarinics)

— Smoking cessation (worsens xerostomia and ILD)

— Avoid sugary candies for dry mouth → use xylitol-based products

— Humidify environment; sip water frequently

— Rheumatology (longitudinal care), ophthalmology, dentistry, oral medicine, and—when relevant—pulmonology, nephrology, neurology

Stratify by burden and organ involvement:

ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index):

Lymphoma risk stratification (high yield):

General management framework:

Modifiable factor optimization:

Multidisciplinary team:

Step 3 management: At diagnosis, establish rheumatology as the home, schedule dental cleanings every 4 months, and arrange annual ophthalmology evaluations to prevent corneal complications and tooth loss—two preventable, high-morbidity outcomes.

Board pearl: Low C4 is the single most powerful lymphoma risk marker in primary Sjögren—remember it for both vignettes and management questions.

Pharmacotherapy — First-Line Drug Regimen

— Preservative-free artificial tears ≥4×/day; gels at night

— Cyclosporine 0.05% ophthalmic or lifitegrast 5% for chronic moderate dry eye

— Topical corticosteroid drops (short course) for flares—ophtho-guided

— Punctal plugs if drops insufficient

— Treat blepharitis: warm compresses, lid hygiene

— Saliva substitutes (carboxymethylcellulose), xylitol lozenges, sugar-free gum

— Pilocarpine 5 mg PO QID (muscarinic agonist) — most effective oral sialogogue

— Adverse effects: sweating, flushing, GI cramping, urinary urgency

— Contraindications: uncontrolled asthma, narrow-angle glaucoma, severe COPD, significant bradyarrhythmia

— Cevimeline 30 mg PO TID — more M3-selective, slightly better tolerated

— High-fluoride toothpaste (1.1% NaF), fluoride trays, chlorhexidine rinses

— Dental visits every 3–4 months; treat candidiasis aggressively (nystatin/clotrimazole)

— First-line for fatigue, arthralgias, myalgias, cutaneous disease

— Evidence for sicca symptoms is mixed but commonly tried

— Baseline + annual ophtho exam (retinal toxicity); ECG if QT risk

— NSAIDs (cautious in renal/GI disease) for transient flares

— Short low-dose prednisone (≤10 mg/day) for synovitis bridge

— Methotrexate or leflunomide if persistent inflammatory arthritis

Xerophthalmia (stepwise):

Xerostomia:

Dental prophylaxis:

Hydroxychloroquine 200–400 mg/day (≤5 mg/kg actual body weight):

Arthritis adjuncts:

Vaginal dryness: non-hormonal lubricants first; topical vaginal estrogen if postmenopausal and severe

Skin care: emollients, sun protection (photosensitivity with anti-Ro)

Step 3 management: Start pilocarpine 5 mg QID for moderate xerostomia after confirming no asthma, glaucoma, or bradyarrhythmia—it improves both saliva and tear flow.

Board pearl: Hydroxychloroquine is the disease-modifying anchor for glandular Sjögren—remember mandatory baseline + annual retinal screening and weight-based dosing to prevent maculopathy.

Procedures / Revascularization / Invasive Management (or expanded pharmacology if non-procedural)

— Severe ILD with declining FVC/DLCO

— Glomerulonephritis or tubulointerstitial nephritis with renal dysfunction

— Cryoglobulinemic vasculitis, mononeuritis multiplex

— Severe cytopenias (hemolytic anemia, immune thrombocytopenia)

— CNS involvement, transverse myelitis

— Prednisone 0.5–1 mg/kg/day for moderate-severe activity; pulse methylprednisolone 500–1000 mg IV ×3 days for life/organ-threatening flares

— Taper over 2–6 months; add steroid-sparing agent

— Methotrexate 15–25 mg/wk — arthritis, mild systemic disease

— Azathioprine 1.5–2.5 mg/kg/day — check TPMT/NUDT15 before initiating

— Mycophenolate 1–3 g/day — preferred for ILD and nephritis

— Cyclophosphamide — severe vasculitis, rapidly progressive GN, refractory neurologic disease

— 1000 mg IV ×2 doses 2 weeks apart

— Strongest evidence for cryoglobulinemic vasculitis, refractory parotitis, severe extraglandular disease, MALT lymphoma

— Pre-treatment: HBV serologies, TB screen, vaccinations

— Punctal occlusion (collagen plugs → permanent cautery) for refractory xerophthalmia

— Sialendoscopy for obstructive parotitis

— Parotidectomy rarely needed except for confirmed lymphoma

— Excisional lymph node biopsy for diagnosis of suspected lymphoma

— Localized: observation, rituximab, or local radiation

— Disseminated: rituximab ± chemotherapy (bendamustine, CHOP-based)

Indications for systemic immunosuppression (organ-threatening disease):

Glucocorticoids:

Steroid-sparing agents (organ-specific):

Rituximab (anti-CD20):

IVIG: for severe sensory ataxic neuropathy or refractory neurologic disease

Procedures:

MALT lymphoma management:

CCS pearl: For a patient admitted with cryoglobulinemic vasculitis + Sjögren, sequence orders: CBC, BMP, UA, cryoglobulins, C3/C4, HCV Ab → methylprednisolone IV pulse → rituximab → plasma exchange if rapidly progressive, and consult rheumatology + nephrology.

Board pearl: Rituximab is the biologic of choice for Sjögren-associated cryoglobulinemic vasculitis and MALT lymphoma.

Special Populations — Elderly and Renal/Hepatic Impairment

— Sicca symptoms common from age-related glandular atrophy and polypharmacy (anticholinergics, diuretics, antihistamines, opioids) — review and deprescribe before labeling SS

— Higher baseline risk of falls with autonomic neuropathy and orthostasis

— Increased baseline lymphoma risk; surveillance threshold lower

— Cognitive screen if new "brain fog" — distinguish from MCI/dementia

— Sweating, urinary urgency, bradycardia more pronounced

— Avoid with significant CAD, angle-closure glaucoma, severe COPD

— Start low (pilocarpine 2.5 mg) and titrate

— Increased risk of hyperglycemia, osteoporosis, infection, delirium

— Add calcium, vitamin D, and bisphosphonate for ≥7.5 mg prednisone equivalent ≥3 months

— Consider PJP prophylaxis if on prednisone ≥20 mg/day for >4 weeks + second immunosuppressant

— Hydroxychloroquine is generally safe but reduce dose if eGFR <30

— Methotrexate contraindicated if eGFR <30; dose-reduce if 30–60

— NSAIDs worsen RTA and CKD — avoid

— Correct hypokalemia from distal RTA with oral potassium citrate (treats acidosis + hypokalemia simultaneously)

— Mycophenolate preferred over cyclophosphamide in moderate CKD when feasible

— Screen for PBC (often coexists — AMA, alk phos) and autoimmune hepatitis (anti-smooth muscle)

— Methotrexate, azathioprine, leflunomide require LFT surveillance; avoid in active liver disease

— Hepatitis C must be ruled out before classifying SS

Elderly considerations:

Pilocarpine/cevimeline in elderly:

NSAIDs: generally avoid in elderly with CKD, CHF, or anticoagulation

Glucocorticoids in elderly:

Renal impairment:

Hepatic impairment:

Step 3 management: In an elderly patient on 5+ medications presenting with new sicca symptoms, the first move is a medication reconciliation to remove anticholinergic burden before initiating an SS workup or pilocarpine.

Board pearl: Potassium citrate treats the distal RTA of Sjögren by replacing K and providing alkali simultaneously—favored over KCl.

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— 2% risk of fetal congenital heart block (CHB) with anti-Ro+; recurrence in subsequent pregnancy ~15–20%

— Risk also includes neonatal lupus rash (transient, photodistributed) and transient cytopenias

— Fetal echo surveillance every 1–2 weeks from 16 to 26 weeks in anti-Ro+ mothers

— Detected 1st-degree AV block → hydroxychloroquine may reduce progression; dexamethasone or betamethasone considered for 2nd-degree block (evidence mixed)

— Established 3rd-degree CHB is irreversible → postnatal pacemaker often needed

— Continue throughout pregnancy and lactation — reduces flares and may reduce CHB recurrence

— Compatible: HCQ, azathioprine, low-dose prednisone, certolizumab

— Avoid: methotrexate, mycophenolate, leflunomide, cyclophosphamide — all teratogenic; counsel reliable contraception

— Rituximab: avoid in 2nd/3rd trimester (B-cell depletion in neonate)

— Methotrexate: stop 3 months before conception (both sexes)

— Leflunomide: cholestyramine washout before conception

— Often presents with recurrent parotitis rather than sicca

— Anti-Ro/La often present; check ANA

— Differential includes juvenile recurrent parotitis, mumps, HIV, IgG4-RD

— Treatment principles similar to adults; pediatric rheumatology referral

— Men present less classically, often with more aggressive systemic disease and higher lymphoma risk

Pregnancy and anti-Ro/SSA:

Hydroxychloroquine in pregnancy:

Other agents:

Breastfeeding: HCQ, prednisone (low dose), azathioprine generally compatible

Fertility counseling:

Pediatric Sjögren (rare):

Sex differences:

Step 3 management: For an anti-Ro+ patient planning pregnancy, continue hydroxychloroquine, document baseline ECG, and arrange MFM co-management with fetal echo schedule 16–26 weeks.

Board pearl: Recurrent parotitis in a child with positive ANA/anti-Ro = juvenile Sjögren—biopsy may be needed because pediatric serologies are less sensitive.

Complications and Adverse Outcomes

— Filamentary keratitis, corneal ulceration, corneal perforation

— Vision loss if untreated keratoconjunctivitis sicca progresses

— Rampant cervical and incisal caries, tooth loss

— Recurrent oral candidiasis, angular cheilitis

— Bacterial sialadenitis (acute Staph parotitis) → warm compresses, sialogogues, antibiotics

— Difficulty wearing dentures, dysgeusia, dysphagia, malnutrition

— Interstitial lung disease (NSIP most common, then UIP, LIP)

— Bronchiectasis, chronic cough

— Pulmonary hypertension (rare)

— Distal RTA with hypokalemia and nephrolithiasis

— Nephrogenic DI, Fanconi syndrome

— Tubulointerstitial nephritis → CKD

— Cryoglobulinemic MPGN

— Small fiber neuropathy (burning pain, normal NCS)

— Sensory ataxic neuronopathy (dorsal root ganglion)

— Trigeminal neuropathy, mononeuritis multiplex

— CNS: optic neuritis, transverse myelitis (NMO overlap — check anti-AQP4)

— Cytopenias, cryoglobulinemia, monoclonal gammopathy

— MALT lymphoma (parotid) — 5–10% lifetime risk; also DLBCL transformation

Ocular:

Oral/dental:

Pulmonary:

Renal:

Neurologic:

Hematologic:

Vascular: Raynaud, cutaneous vasculitis with palpable purpura

OB: congenital heart block, neonatal lupus

Psychosocial: depression, anxiety, sexual dysfunction (vaginal dryness, dyspareunia), profound fatigue limiting work

Mortality drivers: lymphoma, pulmonary disease, severe vasculitis, infection from immunosuppression

Step 3 management: A patient with Sjögren and persistent unilateral parotid enlargement >2 months requires salivary US + imaging + tissue diagnosis—do not assume infection or sialolithiasis.

Board pearl: Painless persistent unilateral parotid mass in known Sjögren = MALT lymphoma until proven otherwise.

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Rapidly progressive ILD with hypoxemia or new oxygen requirement

— Cryoglobulinemic vasculitis with mononeuritis multiplex, rapidly progressive GN, or visceral involvement

— Severe hypokalemia (<2.5) with arrhythmia or weakness from distal RTA

— Acute kidney injury with active urinary sediment

— Severe cytopenias (Hgb <7, platelets <20, neutrophils <500)

— Suspected CNS demyelination (transverse myelitis, optic neuritis)

— Acute bacterial parotitis with sepsis

— Newly diagnosed lymphoma requiring staging and chemotherapy

— Diffuse alveolar hemorrhage

— Respiratory failure from ILD exacerbation

— Hemodynamic instability from sepsis on immunosuppression

— Severe hyperkalemia or symptomatic bradyarrhythmia

— Rheumatology: systemic disease, treatment escalation

— Nephrology: RTA, AKI, biopsy decisions

— Pulmonology: new ILD, declining PFTs

— Neurology: demyelinating disease, severe neuropathy

— Hematology/Oncology: suspected lymphoma

— Ophthalmology: corneal ulceration

— Oral medicine/dentistry: advanced caries, candidiasis

— MFM + Pediatric Cardiology: anti-Ro+ pregnancy with fetal AV block

— Reconcile immunosuppression at discharge; document PJP prophylaxis if indicated (prednisone ≥20 mg/day >4 weeks on second agent)

— Schedule rheumatology within 2 weeks of discharge

— Ensure vaccinations up to date before rituximab if elective

Inpatient admission indications:

ICU triage:

Consultations to mobilize early:

Transitions of care priorities (Step 3 emphasis):

CCS pearl: For a hospitalized patient with new SS-related ILD, sequence: CBC, BMP, ANA, anti-Ro/La, anti-Scl70, anti-Jo1, HRCT chest, PFTs with DLCO, echo, infectious workup → start IV methylprednisolone → consult rheum + pulm → discuss mycophenolate vs rituximab, and arrange post-discharge PFTs in 4–6 weeks.

Board pearl: Suspect lymphoma before initiating immunosuppression in a Sjögren patient with B symptoms, lymphadenopathy, or new cytopenias—biopsy first.

Key Differentials — Same-Category Causes

— Systemic lupus erythematosus:

— Photosensitive malar rash, oral ulcers, serositis, GN, low complement, anti-dsDNA/anti-Sm

— Sicca occurs but is less dominant

— Rheumatoid arthritis:

— Erosive symmetric polyarthritis, anti-CCP positive, rheumatoid nodules

— Secondary SS overlay common (~10–30%)

— Systemic sclerosis:

— Skin thickening, Raynaud, telangiectasias, GI dysmotility, anti-Scl70 or anti-centromere

— Secondary SS common; sicca from glandular fibrosis

— Mixed connective tissue disease:

— Raynaud, swollen hands, myositis, anti-U1-RNP

— Inflammatory myopathies (dermatomyositis/polymyositis):

— Proximal weakness, elevated CK, anti-Jo1; sicca less prominent

— Mikulicz-like presentation with bilateral lacrimal and salivary gland enlargement

— Elevated IgG4 levels; storiform fibrosis with IgG4+ plasma cells on biopsy

— Multi-organ: autoimmune pancreatitis, retroperitoneal fibrosis, tubulointerstitial nephritis

— Anti-Ro/La negative; responds dramatically to glucocorticoids

— Bilateral parotid swelling (Heerfordt syndrome: parotitis, uveitis, fever, facial palsy)

— Hilar adenopathy, hypercalcemia, elevated ACE, non-caseating granulomas

— Macroglossia, periorbital purpura, infiltrative organ disease

— Biopsy with Congo red staining

— History of allogeneic HSCT, multi-organ involvement

Other autoimmune/connective tissue diseases with sicca:

IgG4-related disease:

Sarcoidosis:

Amyloidosis:

Graft-versus-host disease (chronic):

Key distinction: IgG4-RD mimics Sjögren clinically but has negative anti-Ro/La, elevated IgG4, and characteristic histology—biopsy with IgG4 stain is the discriminator.

Board pearl: Heerfordt syndrome (parotitis + anterior uveitis + facial palsy + fever) = sarcoidosis, not Sjögren—check chest imaging and ACE.

Key Differentials — Other-Category Causes

— Anticholinergics, antihistamines, TCAs, SSRIs, antipsychotics, opioids, diuretics, antimuscarinics (oxybutynin), antihypertensives (clonidine)

— Dose-related, no autoantibodies, reversible

— Hepatitis C: sicca, cryoglobulinemia, mimics SS — check HCV Ab/RNA

— HIV: DILS (diffuse infiltrative lymphocytosis syndrome) with CD8+ infiltration of glands, parotid enlargement, sicca

— HTLV-1, EBV, mumps, CMV

— Bacterial sialadenitis: acute, painful, often unilateral, fever, purulent expression from duct

— Diabetes mellitus — autonomic neuropathy, dehydration, candidiasis

— Hypothyroidism — coexists with SS; check TSH

— Dehydration from any cause

— Sialolithiasis — recurrent unilateral postprandial swelling

— Salivary gland tumors (pleomorphic adenoma, Warthin, mucoepidermoid carcinoma) — unilateral mass

— Anorexia/bulimia — bilateral parotid hypertrophy ("chipmunk cheeks") with normal sicca workup

— Mouth breathing, CPAP use, untreated OSA → xerostomia

— Smoking, cannabis use

— Aging-related glandular atrophy

— Stevens-Johnson/TEN sequelae, ocular cicatricial pemphigoid, GVHD — chronic ocular surface disease without serologic SS

Drug-induced sicca:

Infectious causes:

Radiation: prior head/neck radiotherapy permanently damages salivary/lacrimal glands

Endocrine/metabolic:

Salivary gland infiltrative/obstructive:

Behavioral/neurologic:

Mucous membrane disorders:

Diabetes insipidus and chronic dehydration — dry mouth without glandular pathology

Key distinction: HCV with cryoglobulinemia can produce sicca, low C4, RF, and even anti-Ro positivity—always screen for HCV before labeling primary SS, especially when cryoglobulinemia is present.

Board pearl: Bilateral parotid enlargement + low CD4 count = HIV-associated DILS, not primary SS—check HIV status.

Secondary Prevention / Discharge Medications / Long-Term Plan

— Hydroxychloroquine continued indefinitely if tolerated and effective

— Steroid taper to lowest effective dose; aim ≤5 mg prednisone/day for chronic maintenance

— Steroid-sparing agent (MTX, AZA, MMF) per organ involvement

— Rituximab redosing every 6 months for refractory/relapsing disease

— Preservative-free artificial tears, gels at night

— Cyclosporine 0.05% or lifitegrast for chronic dry eye

— Pilocarpine or cevimeline as tolerated

— High-fluoride toothpaste, daily fluoride trays

— Calcium 1000–1200 mg/day + vitamin D 800–1000 IU/day

— Bisphosphonate if prednisone ≥7.5 mg/day for ≥3 months or fragility risk

— DEXA at baseline and every 1–2 years

— Chronic inflammation increases CV risk; statin per ASCVD risk, BP control, A1c management

— Counsel smoking cessation, aerobic exercise

— Routine clinical exam for lymphadenopathy and parotid changes at every visit

— Annual CBC, SPEP, C3/C4

— Salivary gland ultrasound at intervals if high-risk features

— Age-appropriate cancer screening (mammography, colonoscopy, Pap, lung CT)

— Annual influenza (inactivated), pneumococcal series (PCV20 or PCV15+PPSV23), recombinant zoster vaccine (Shingrix) — preferentially before immunosuppression

— Avoid live vaccines on biologics or high-dose immunosuppression

— COVID-19 boosters per current schedule

— Consider PJP prophylaxis (TMP-SMX) when high-dose steroid + second agent

Maintenance pharmacotherapy:

Sicca regimen (daily, indefinite):

Bone health (any chronic steroid use):

Cardiovascular risk reduction:

Cancer surveillance:

Infection prevention:

Patient self-care: humidifier at night, lid hygiene, hydration, avoid caffeine/alcohol excess

Step 3 management: At each visit, document medication reconciliation, vaccine status, DEXA timing, and lymphoma surveillance exam—the four pillars of longitudinal SS care.

Board pearl: Shingrix is preferred over live zoster vaccine and should be given before starting biologic therapy when possible.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Rheumatology: every 3–6 months stable; every 4–8 weeks during active disease or treatment initiation

— Ophthalmology: annually; more often with chronic keratopathy or HCQ use (formal retinal screen baseline + annual after 5 years)

— Dentistry: every 3–4 months

— Oral medicine: as needed for candidiasis, dysgeusia, oral pain

— CBC, CMP (LFTs, Cr, K+), UA

— ESR, CRP, C3/C4, immunoglobulins, SPEP

— Disease activity (ESSDAI) and patient-reported (ESSPRI) indices

— HCQ: baseline ophtho + annual after 5 years; ECG if QT risk

— MTX: CBC, LFTs, Cr every 4–12 weeks; folate 1 mg/day

— Azathioprine: TPMT/NUDT15 baseline; CBC, LFTs every 4–12 weeks

— MMF: CBC, LFTs every 4–12 weeks; pregnancy testing

— Rituximab: CBC, immunoglobulins, HBV monitoring; infusion reactions

— PFTs with DLCO annually if ILD or anti-Ro+ with respiratory symptoms

— HRCT if new dyspnea, cough, or declining PFTs

— Renal: UA, BMP every 3–6 months; urine pH if RTA suspected

— Salivary gland US for high lymphoma risk

— Fatigue management: pacing, sleep hygiene, screen for OSA and depression, graded aerobic exercise

— Nutrition counseling: soft moist diet, avoid acidic/sugary foods, adequate protein

— Speech/swallow therapy if dysphagia

— Mental health support; cognitive behavioral therapy for chronic disease

— Sexual health: vaginal moisturizers, lubricants, address dyspareunia

— Support groups (Sjögren's Foundation)

Visit cadence:

Lab monitoring (every 3–6 months baseline):

Drug-specific monitoring:

Organ-specific surveillance:

Rehabilitation and counseling:

Step 3 management: At every encounter, screen for fatigue, mood, dental health, and lymph node exam—these four catch the majority of meaningful longitudinal complications.

Board pearl: Fatigue is the most disabling symptom—screen for OSA, anemia, hypothyroidism, depression, and vitamin D deficiency before attributing solely to SS.

Ethical, Legal, and Patient Safety Considerations

— Discuss infection risk, malignancy risk (especially with cyclophosphamide), fertility implications (gonadotoxicity of cyclophosphamide → offer GnRH agonist or sperm/oocyte cryopreservation beforehand)

— Document teratogenicity counseling with MTX, MMF, leflunomide, cyclophosphamide; require two forms of contraception in patients of reproductive potential

— Anti-Ro+ patients deserve preconception counseling about 2% CHB risk and 15–20% recurrence in subsequent pregnancies

— Discuss continued hydroxychloroquine, fetal echo schedule, MFM referral

— At hospital discharge after immunosuppression initiation: reconcile PJP prophylaxis, vaccination status, taper schedule, and rheumatology follow-up within 2 weeks

— Communicate active issues to PCP and dentist; medication list to pharmacy

— Patients on biologics need infection action plan: when to hold doses, when to seek care for fever

— Look-alike/sound-alike: methotrexate is weekly, not daily—medication errors cause severe toxicity; emphasize at every prescription

— Black box warnings: TNF inhibitors (rarely used in SS), JAK inhibitors → MACE, malignancy, VTE

— Counsel on sun protection (photosensitivity, skin cancer risk)

— Report TB conversion before starting biologics; treat latent TB

— Hepatitis B reactivation risk with rituximab → screen, prophylax with entecavir or tenofovir if HBsAg+ or HBcAb+

— Confirm capacity to manage complex regimens; involve caregivers; consider pillboxes

— Fatigue and ocular symptoms often qualify for ADA workplace accommodations (humidified environment, frequent breaks)

— Severe dry eye affects visual function; advise ophthalmology clearance if uncertain

Informed consent for immunosuppression:

Pregnancy counseling and shared decision-making:

Transitions of care (high Step 3 yield):

Patient safety:

Mandatory reporting and public health:

Capacity and elderly:

Disability and work accommodation:

Driving safety:

Ethical pearl: Respect patient autonomy in declining immunosuppression for non-organ-threatening disease, but document risks of progression.

Step 3 management: Before initiating rituximab, complete a safety bundle: HBV/HCV/HIV/TB screen, vaccinations updated, pregnancy test, informed consent including infection and infusion-reaction risks—then schedule first infusion with monitoring.

High-Yield Associations and Rapid-Fire Clinical Facts

Anti-Ro/SSA → neonatal lupus and congenital heart block; can be present without classic sicca

Anti-La/SSB rarely positive without anti-Ro

Low C4 + cryoglobulinemia + palpable purpura = highest lymphoma risk triad

MALT lymphoma of parotid = most common SS-associated malignancy

Distal (type 1) RTA + hypokalemia + nephrocalcinosis = classic renal SS

Hypergammaglobulinemia with normal CRP = SS clue

Annular erythema = cutaneous SS, especially in Asian patients

Sensory ataxic neuronopathy (positive Romberg, pseudoathetosis) = dorsal root ganglionitis

Schirmer ≤5 mm/5 min + focus score ≥1 = key diagnostic anchors

Pilocarpine = muscarinic agonist for xerostomia; cevimeline = M3-selective alternative

Hydroxychloroquine = first-line systemic agent; mandatory annual retinal screen after 5 years

Rituximab for cryoglobulinemic vasculitis, refractory parotitis, MALT lymphoma

HCV must be excluded before labeling primary SS (cryoglobulinemia mimic)

HIV → DILS mimics SS with parotid enlargement and CD8 infiltrates

IgG4-RD mimics SS with Mikulicz-like picture but is anti-Ro negative and steroid-responsive

Heerfordt syndrome (parotitis + uveitis + facial palsy + fever) = sarcoidosis

Cracker sign + cervical caries + bilateral parotid swelling = classic SS vignette

Fetal echo 16–26 weeks in anti-Ro+ pregnancies

Potassium citrate = preferred replacement in SS-related distal RTA (alkali + K)

Persistent unilateral parotid mass in known SS = lymphoma until proven otherwise

ANA + RF common in SS — does not equal RA without anti-CCP and erosive disease

Most common cause of death (excess): lymphoma, ILD, vasculitis, infection

ESSDAI = systemic activity score; ESSPRI = patient-reported symptom score

Board pearl: SS is the rheumatologic condition with the highest lymphoma risk of all autoimmune diseases—this single fact drives surveillance philosophy.

Key distinction: Anti-Ro positivity alone is not diagnostic—needs objective sicca evidence (biopsy, Schirmer, salivary flow, or ocular staining) to meet classification criteria.

Board Question Stem Patterns

— 52-year-old woman with 8 months of gritty eyes, dry mouth, and difficulty swallowing crackers; exam shows fissured tongue and bilateral parotid fullness. Anti-Ro+, Schirmer 3 mm.

— Answer: Diagnose Sjögren; start preservative-free tears, fluoride, pilocarpine, and hydroxychloroquine

— Woman with chronic muscle weakness, K+ 2.8, non-anion-gap acidosis, urine pH 6.5, and dry mouth.

— Answer: Distal RTA from SS → potassium citrate; check anti-Ro/La

— Pregnant woman with anti-Ro+; fetal heart rate 65 at 22 weeks.

— Answer: Fetal AV block; manage with fetal echo surveillance, MFM, consider steroids; postnatal pacemaker for complete block

— Known SS with new persistent unilateral parotid mass, low C4, and new lymphadenopathy.

— Answer: Biopsy for MALT lymphoma

— Palpable purpura, mononeuritis multiplex, low C4, positive cryocrit.

— Answer: Pulse steroids + rituximab; rule out HCV

— Woman with chronic cough, bibasilar crackles, anti-Ro+, HRCT shows NSIP pattern.

— Answer: SS-associated ILD; mycophenolate ± steroids

— Bilateral lacrimal + salivary swelling, elevated IgG4, anti-Ro negative, autoimmune pancreatitis.

— Answer: IgG4-related disease, not SS

— Elderly woman on amitriptyline, oxybutynin, and diphenhydramine with dry mouth and eyes, negative serologies.

— Answer: Deprescribe anticholinergics before further workup

— Newborn of mother with anti-Ro+ presents with bradycardia and rash.

— Answer: Neonatal lupus + CHB

— Patient on HCQ for 6 years without ophthalmology screen.

— Answer: Order annual retinal exam (mandatory after 5 years)

Pattern 1 — Classic sicca vignette:

Pattern 2 — Hidden renal disease:

Pattern 3 — Anti-Ro pregnancy:

Pattern 4 — Lymphoma red flag:

Pattern 5 — Cryoglobulinemic vasculitis:

Pattern 6 — ILD presentation:

Pattern 7 — Mimic question:

Pattern 8 — Drug-induced sicca:

Pattern 9 — Neonatal lupus:

Pattern 10 — Monitoring trap:

Board pearl: Step 3 frequently tests management sequences (e.g., "next best step")—the discriminators are typically screening before treatment (HCV, TB, HBV, pregnancy, vaccines) and prophylaxis (PJP, bone, vaccines).

One-Line Recap

Sjögren syndrome is a female-predominant autoimmune exocrinopathy diagnosed by combining sicca symptoms with objective glandular dysfunction (Schirmer, salivary flow, biopsy with focus score ≥1) and serologies (anti-Ro/SSA), managed with sicca-directed therapy (artificial tears, pilocarpine, fluoride), hydroxychloroquine for systemic glandular disease, and immunosuppression (steroids, MMF, rituximab) for organ-threatening manifestations, with vigilant lifelong surveillance for MALT lymphoma.

Diagnosis anchor: Sicca + anti-Ro/SSA, or focus score ≥1 on labial gland biopsy in seronegative patients (2016 ACR/EULAR criteria); always rule out HCV, HIV, IgG4-RD, sarcoidosis, prior radiation.

Management ladder: Preventive (artificial tears, fluoride, dental visits every 3–4 months, humidified environment) → symptomatic sialogogues (pilocarpine, cevimeline) → hydroxychloroquine for glandular/MSK/cutaneous disease → glucocorticoids + steroid-sparing agents (MMF for ILD/GN, MTX/AZA for arthritis) → rituximab for cryoglobulinemic vasculitis, refractory parotitis, or MALT lymphoma.

Pregnancy and special populations: Anti-Ro+ pregnancies require fetal echo from 16–26 weeks to detect congenital heart block; continue HCQ throughout pregnancy; treat distal RTA with potassium citrate; deprescribe anticholinergics in elderly before labeling SS.

Surveillance imperative: Sjögren carries the highest lymphoma risk of any autoimmune disease (~5–10% lifetime, mostly parotid MALT); persistent unilateral parotid mass, lymphadenopathy >1.5 cm, low C4, cryoglobulinemia, monoclonal gammopathy, and lymphopenia are red flags warranting tissue diagnosis—annual labs (CBC, SPEP, C3/C4), clinical exam, and vaccine optimization (pneumococcal, influenza, Shingrix before biologics) anchor longitudinal care.

Board pearl: When in doubt on Step 3, the highest-yield next steps are screen before treat (HCV/HIV/TB/HBV/pregnancy/vaccines), prevent before progress (fluoride, calcium/vitamin D/bisphosphonate on steroids, PJP prophylaxis), and biopsy before immunosuppress any unexplained mass or lymphadenopathy.